BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brás IC, Outeiro TF. Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies. Cells 2021;10:375. [PMID: 33673034 DOI: 10.3390/cells10020375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Golan H, Volkov O, Shalom E. Nuclear imaging in Parkinson's disease: The past, the present, and the future. Journal of the Neurological Sciences 2022. [DOI: 10.1016/j.jns.2022.120220] [Reference Citation Analysis]
2 Hsu YL, Hung HS, Tsai CW, Liu SP, Chiang YT, Kuo YH, Shyu WC, Lin SZ, Fu RH. Peiminine Reduces ARTS-Mediated Degradation of XIAP by Modulating the PINK1/Parkin Pathway to Ameliorate 6-Hydroxydopamine Toxicity and α-Synuclein Accumulation in Parkinson's Disease Models In Vivo and In Vitro. Int J Mol Sci 2021;22:10240. [PMID: 34638579 DOI: 10.3390/ijms221910240] [Reference Citation Analysis]
3 Santos J, Pallarès I, Ventura S. Is a cure for Parkinson’s disease hiding inside us? Trends in Biochemical Sciences 2022. [DOI: 10.1016/j.tibs.2022.02.001] [Reference Citation Analysis]
4 Jellinger KA, Wenning GK, Stefanova N. Is Multiple System Atrophy a Prion-like Disorder? Int J Mol Sci 2021;22:10093. [PMID: 34576255 DOI: 10.3390/ijms221810093] [Reference Citation Analysis]
5 Menon S, Armstrong S, Hamzeh A, Visanji NP, Sardi SP, Tandon A. Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies. Front Neurol 2022;13:852003. [DOI: 10.3389/fneur.2022.852003] [Reference Citation Analysis]
6 Rosado-Ramos R, Godinho-Pereira J, Marques D, Figueira I, Fleming Outeiro T, Menezes R, Nunes Dos Santos C. Small Molecule Fisetin Modulates Alpha-Synuclein Aggregation. Molecules 2021;26:3353. [PMID: 34199487 DOI: 10.3390/molecules26113353] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Mishra A, Bandopadhyay R, Singh PK, Mishra PS, Sharma N, Khurana N. Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside. Metab Brain Dis 2021. [PMID: 34387831 DOI: 10.1007/s11011-021-00806-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Sarchione A, Marchand A, Taymans JM, Chartier-Harlin MC. Alpha-Synuclein and Lipids: The Elephant in the Room? Cells 2021;10:2452. [PMID: 34572099 DOI: 10.3390/cells10092452] [Reference Citation Analysis]
9 Venezia S, Kaufmann WA, Wenning GK, Stefanova N. Toll-like receptor 4 deficiency facilitates α-synuclein propagation and neurodegeneration in a mouse model of prodromal Parkinson's disease. Parkinsonism Relat Disord 2021;91:59-65. [PMID: 34530328 DOI: 10.1016/j.parkreldis.2021.09.007] [Reference Citation Analysis]
10 Kuo MC, Liu SC, Hsu YF, Wu RM. The role of noncoding RNAs in Parkinson's disease: biomarkers and associations with pathogenic pathways. J Biomed Sci 2021;28:78. [PMID: 34794432 DOI: 10.1186/s12929-021-00775-x] [Reference Citation Analysis]
11 Lee BE, Suh PG, Kim JI. O-GlcNAcylation in health and neurodegenerative diseases. Exp Mol Med 2021;53:1674-82. [PMID: 34837015 DOI: 10.1038/s12276-021-00709-5] [Reference Citation Analysis]
12 Baron T, Arsac JN, Verchère J, Tlili H, Aufauvre C, Bétemps D. Co-expression of APP/PS1 disrupts the distribution of brain lesions in a synucleinopathy transgenic mouse model (M83). Acta Neuropathol 2022. [PMID: 35257220 DOI: 10.1007/s00401-022-02410-x] [Reference Citation Analysis]
13 Wang Y, Gao L, Chen J, Li Q, Huo L, Wang Y, Wang H, Du J. Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson's Disease. Front Pharmacol 2021;12:757161. [PMID: 34887759 DOI: 10.3389/fphar.2021.757161] [Reference Citation Analysis]